 LONDON, Jan. 04, 2021 GLOBE NEWSWIRE -- Freeline Therapeutics Holdings plc Nasdaq: FRLN the Company or Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced they will participate virtually at conferences during January 2021. 